Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions
Interventions
pepinemab + pembrolizumab
Locations
15
United States
Highlands Oncology Group, PA - North Hills
Springdale, Arkansas, United States
California Cancer Associates for Research and Excellence (CCARE)-Fresno
Fresno, California, United States
UCSF Medical Center at Mission Bay
San Francisco, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
AdventHealth Celebration
Celebration, Florida, United States
AdventHealth Orlando
Orlando, Florida, United States
Start Date
August 9, 2021
Primary Completion Date
July 24, 2024
Completion Date
July 24, 2024
Last Updated
January 8, 2025
Lead Sponsor
Vaccinex Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions